BioSpace News Archive

NewAmsterdam Pharma Company N.V. announced the appointment of John W. Smither as an independent director to its Board of Directors.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events on February-March.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announces the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) as part of a triple combination therapy with standard-of-care anti-PD-1 therapy and chemotherapy.

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”) today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule PIM kinase inhibitor that is being developed by the Company’s wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”), as a potential therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced the initiation of its second investigator initiated studies (IIS) in a series of planned clinical studies.

Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, today unveiled a purpose-built software platform designed specifically to provide drug trial sponsors and sites a seamless way to manage complex, mission-critical, and time-sensitive moments on the patient journey

Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced it has entered into a new research collaboration with Poland-based biopharmaceutical company Pure Biologics to evaluate two of Pure Biologics’ very early stage assets in a Phase 0 intratumoral microdosing study.

RNAimmune, Inc. announced today that its RNAimmune mRNA cancer vaccine program has been accepted for oral presentation at the AACR Annual Meeting 2023.

Scholar Rock today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.

Align Technology, Inc. today announced that it has entered into a new accelerated stock repurchase agreement (“ASR”) with Citibank, N.A. (“Citi”), to repurchase $250 million of Align’s common stock under Align’s $1.0 billion stock repurchase program announced on May 13, 2021.